Drug Research
Pfizer and BioNTech Receive First U.S. FDA EUA of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
Pfizer Inc. and BioNTech SE announced that the U.S. FDA has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as 5 to <12 years). For this age group,...
Drug Research
WuXi Biologics Launches a New GMP Commercial Drug Product Facility
WuXi Biologics, a global company with leading open-access biologics technology platforms, announced it has successfully launched the GMP operation of its new drug product facility located in Wuxi, China, which is the eighth operational drug product facility in the...
Drug Research
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, announced that the National Agency of Drug and...
Drug Research
BioNTech Plans to Initiate the Construction of an mRNA Vaccine Manufacturing Facility in Africa in mid-2022
BioNTech SE announced that the Company plans to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022. This is the next step in BioNTech’s efforts to implement sustainable end-to-end vaccine...
Drug Research
Istari Oncology Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its Viral Immunotherapy PVSRIPO
FUJIFILM Diosynth Biotechnologies (FDB) and Istari Oncology announced that they have entered into an agreement for the manufacturing of Istari Oncology’s viral immunotherapy, PVSRIPO, currently being investigated for the treatment of solid tumors.
FUJIFILM Diosynth Biotechnologies is a leading Contract...
Drug Research
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the U.S. FDA has authorized for emergency use a booster dose of the Moderna COVID-19 vaccine (mRNA-1273) at the 50 µg dose level for people...
Drug Research
Enesi Pharma inks pact with NIH to evaluate ImplaVax-enabled flu vaccines
Enesi Pharma has entered into an agreement with the US National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to test a novel ImplaVax enabled pandemic flu vaccine.
ImplaVax-enabled vaccination products leverage Enesi's innovative unit solid-dose,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
